54
Participants
Start Date
April 26, 2012
Primary Completion Date
April 4, 2017
Study Completion Date
April 4, 2017
Anti-HBV nucleoside/nucleotide therapy
Subjects with chronic HBV infection and with decompensated liver disease who are receiving or anticipated to receive anti-HBV nucleoside/nucleotide therapy will be identified at centers with liver disease expertise where subjects are monitored on a regular basis.
Icahn School of Medicine at Mount Sinai, New York
Georgetown University Hospital, Washington D.C.
Virginia Commonwealth University, Richmond
Emory University Hospital, Atlanta
Florida Hospital Transplant, Orlando
Jackson Memorial Hospital, Miami
Vanderbilt University Medical Center, Nashville
Methodist University Hospital, Memphis
Henry Ford Health System, Detroit
Northwestern University, Chicago
Saint Louis University Hospital, St Louis
University of Kansas Medical Center, Kansas City
Alegent Creighton Health, Omaha
Baylor All Saints Medical Center, Fort Worth
The Methodist Hospital, Houston
Cedars-Sinai Medical Center for Liver Diseases and Transplantation, Los Angeles
University of California Los Angeles, Los Angeles
University of California at San Francisco Medical Center, San Francisco
Stanford University, Palo Alto
Oregon Health and Science University, Portland
Harborview Medical Center, Seattle
Yale University School of Medicine, New Haven
Beth Israel Deaconess Medical Center, Boston
University of Calgary, Calgary
Vancouver General Hospital, Vancouver
Vancouver ID Research and Care Centre Society, Vancouver
Toronto Liver Centre, Toronto
Lead Sponsor
Gilead Sciences
INDUSTRY